David A. Spellman - Jun 8, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, CFO and Treasurer
Signature
/s/ Carolyn Rucci, attorney-in-fact for David A. Spellman
Stock symbol
AKBA
Transactions as of
Jun 8, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 08:11 AM
Previous filing
Mar 2, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +200K +155.52% $0.00 329K Jun 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +200K $0.00 200K Jun 8, 2022 Common Stock 200K $0.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.
F2 The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.